Log in

NASDAQ:NEONeoGenomics Stock Price, Forecast & News

$33.88
+0.62 (+1.86 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.14
Now: $33.88
$34.29
50-Day Range
$25.65
MA: $28.01
$33.88
52-Week Range
$18.52
Now: $33.88
$34.97
Volume1.36 million shs
Average Volume1.16 million shs
Market Capitalization$3.57 billion
P/E Ratio1,129.71
Dividend YieldN/A
Beta0.76
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Read More
NeoGenomics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$408.83 million
Cash Flow$0.52 per share
Book Value$4.86 per share

Profitability

Net Income$8.01 million

Miscellaneous

Employees1,700
Market Cap$3.57 billion
Next Earnings Date7/28/2020 (Confirmed)
OptionableOptionable

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

How has NeoGenomics' stock been impacted by COVID-19 (Coronavirus)?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 36.7% and is now trading at $33.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NeoGenomics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NeoGenomics.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for NeoGenomics.

How can I listen to NeoGenomics' earnings call?

NeoGenomics will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings results on Tuesday, April, 28th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.04. The medical research company earned $106.03 million during the quarter, compared to the consensus estimate of $106.03 million. NeoGenomics had a return on equity of 2.94% and a net margin of 0.82%. The business's revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.03) EPS. View NeoGenomics' earnings history.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $106-106 million, compared to the consensus revenue estimate of $104.42 million.

What price target have analysts set for NEO?

10 brokerages have issued 1 year price targets for NeoGenomics' stock. Their forecasts range from $9.00 to $38.00. On average, they expect NeoGenomics' stock price to reach $31.00 in the next year. This suggests that the stock has a possible downside of 8.5%. View analysts' price targets for NeoGenomics.

Has NeoGenomics been receiving favorable news coverage?

Headlines about NEO stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NeoGenomics earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news about NeoGenomics.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Square (SQ), Cisco Systems (CSCO), Inseego (INSG), Advanced Micro Devices (AMD) and Crispr Therapeutics (CRSP).

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
  • Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
  • Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)
  • Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $33.88.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $3.57 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.